Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
A Neuroleptic Malignantlike Syndrome Due to Levodopa Therapy Withdrawal
JAMA 254:2792-2795, Friedman,J.H.,et al, 1985
Alternate Day Levodopa Therapy in Parkinsonism
Neurol 32:324-326, Koller,W.C., 1982
Complications of Chronic Levodopa Therapy; Long-term Efficacy of Drug Holiday
Neurol 31:473-476, Koller,W.C.,et al, 1981
Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
A 56-year-old Man with Cognitive Impairment and Difficulty Tying his Necktie
Neurol 85:e116-e122, Baker, J.M.,et al, 2015
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Deprenyl Effects of Levodopa Pharmacodynamics, Mood, and Free Radical Scavenging
Neurol 42:541-544, Baronti,F.,et al, 1992
Apomorphine Test for Dopaminergic Response in Pts with Previously Untreated Parkinson's
Arch Neurol 49:1131-1134, Gasser,T.,et al, 1992
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Levodopa-Induced Myoclonus
Arch Neurol 32:331-334, Klawans,H.L., 1975